{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Safety+and+Pharmacokinetics", "query": { "condition": "Safety and Pharmacokinetics" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 6491, "total_pages": 650, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Safety+and+Pharmacokinetics&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-25T03:48:36.590Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04246086", "title": "A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Follicular Lymphoma" ], "interventions": [ { "name": "Mosunetuzumab (IV)", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Mosunetuzumab (SC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 237, "start_date": "2020-08-12", "completion_date": "2030-09-06", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-09-25T03:48:36.590Z", "location_count": 13, "location_summary": "Duarte, California • Miami, Florida • Louisville, Kentucky + 9 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Baton Rouge", "state": "Louisiana" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04246086" }, { "nct_id": "NCT06717269", "title": "A Single and Multiple Ascending Doses, Relative Bioavailability, Food Effect, and Drug-Drug Interaction Study of NX-5948 in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer" ], "interventions": [ { "name": "NX-5948", "type": "DRUG" }, { "name": "Esomeprazole", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Famotidine", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Digoxin", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Quinidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nurix Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "19 Years to 55 Years" }, "enrollment_count": 223, "start_date": "2024-11-30", "completion_date": "2026-05-01", "has_results": false, "last_update_posted_date": "2026-07-28", "last_synced_at": "2026-09-25T03:48:36.590Z", "location_count": 2, "location_summary": "Phoenix, Arizona • Lincoln, Nebraska", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT06717269" }, { "nct_id": "NCT02804568", "title": "A Phase 1 Safety Study in Adults With Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "ALKS 3831", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alkermes, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 42, "start_date": "2016-06", "completion_date": "2016-08", "has_results": false, "last_update_posted_date": "2016-09-22", "last_synced_at": "2026-09-25T03:48:36.590Z", "location_count": 3, "location_summary": "Little Rock, Arkansas • Clementon, New Jersey • Dayton, Ohio", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Clementon", "state": "New Jersey" }, { "city": "Dayton", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02804568" }, { "nct_id": "NCT06544642", "title": "A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers", "Sjögren's Syndrome" ], "interventions": [ { "name": "ASP5502", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 116, "start_date": "2024-08-21", "completion_date": "2026-03-05", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-09-25T03:48:36.590Z", "location_count": 1, "location_summary": "Daytona Beach, Florida", "locations": [ { "city": "Daytona Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06544642" }, { "nct_id": "NCT01406470", "title": "Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN™ in Subjects With Primary Immunodeficiency", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Immunologic Deficiency Syndrome" ], "interventions": [ { "name": "Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Green Cross Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "2 Years to 70 Years" }, "enrollment_count": 45, "start_date": "2011-09", "completion_date": "2013-07", "has_results": false, "last_update_posted_date": "2014-01-10", "last_synced_at": "2026-09-25T03:48:36.590Z", "location_count": 9, "location_summary": "Birmingham, Alabama • North Palm Beach, Florida • Chicago, Illinois + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "North Palm Beach", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01406470" }, { "nct_id": "NCT03520517", "title": "Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Amyotrophic Lateral Sclerosis", "ALS", "Lou Gehrig Disease", "Lou Gehrig's Disease", "Lou-Gehrigs Disease", "Motor Neuron Disease, Amyotrophic Lateral Sclerosis" ], "interventions": [ { "name": "BHV-0223", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biohaven Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2018-02-02", "completion_date": "2018-10-08", "has_results": false, "last_update_posted_date": "2022-10-06", "last_synced_at": "2026-09-25T03:48:36.590Z", "location_count": 5, "location_summary": "Fort Lauderdale, Florida • Lincoln, Nebraska • Charlotte, North Carolina + 2 more", "locations": [ { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Lincoln", "state": "Nebraska" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Cordova", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03520517" }, { "nct_id": "NCT07586618", "title": "First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoblastic Lymphoma", "Acute Lymphoblastic Leukemia ALL" ], "interventions": [ { "name": "4A10", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Allterum Therapeutics, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2026-06-01", "completion_date": "2028-09", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-09-25T03:48:36.590Z", "location_count": 7, "location_summary": "Aurora, Colorado • Indianapolis, Indiana • New York, New York + 4 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "New York", "state": "New York" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07586618" }, { "nct_id": "NCT01757860", "title": "Safety and Pharmacokinetics Study of CARD-024 in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug Safety", "Heart; Disease, Activity" ], "interventions": [ { "name": "CARD-024", "type": "DRUG" }, { "name": "Drug Carrier", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Cardiavent Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 34, "start_date": "2011-09", "completion_date": "2012-01", "has_results": false, "last_update_posted_date": "2012-12-31", "last_synced_at": "2026-09-25T03:48:36.590Z", "location_count": 1, "location_summary": "Kalamazoo, Michigan", "locations": [ { "city": "Kalamazoo", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01757860" }, { "nct_id": "NCT02881320", "title": "Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "B/F/TAF (Adult Strength)", "type": "DRUG" }, { "name": "B/F/TAF (Low Dose)", "type": "DRUG" }, { "name": "B/F/TAF (TOS)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Month to 17 Years" }, "enrollment_count": 177, "start_date": "2016-09-21", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-09-25T03:48:36.590Z", "location_count": 10, "location_summary": "Washington D.C., District of Columbia • Ft. Pierce, Florida • Gainesville, Florida + 7 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Ft. Pierce", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02881320" }, { "nct_id": "NCT00732420", "title": "Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumours" ], "interventions": [ { "name": "topotecan", "type": "DRUG" }, { "name": "pazopanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2008-09-24", "completion_date": "2013-06-12", "has_results": false, "last_update_posted_date": "2017-11-13", "last_synced_at": "2026-09-25T03:48:36.590Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00732420" } ] }